Platelets and RBCS Changes Underlie Cardiovascular Diseases, in the COVID-19 Era

Bahram Alamdary Badlou

PhD Hematology and Drs. Medical Biology, Cardiology; BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands

Dr. Bahram Alamdary Badlou, PhD Hematology and Drs. Medical Biology, Cardiology; BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands.

Keywords: Platelets; COVID-19; Neutrophils

Abstract

Worldwide all countries are distressed from COVID-19 outbreaks, causing more than 260 million infections, and 5.3 million deaths (and counting). Globally compared, the US, Russia, and European countries have less than 20% population but are suffering from more than 50?ath cases (Dec-2021). Different unspecific drugs and (in-)effective vaccines cause extraordinary increased morbidity and mortality rates, of which the exact mechanisms are not elucidated yet. Platelets (PLTs) play a pivotal role not only in Thrombosis and Haemostasis (T&H), blood clotting, cancerogenic metastatic processes but also in mortal consequences of abused anticoagulants. Nonetheless, PLTs are affected by COVID-19 variants(-vaccines), which is resulting in different uncontrolled and severe clinical episodes, and an increase in morbidity and mortality rates [1].

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).